Salvage of refractory post-transfusion hyperhaemolysis by targeting hyperinflammation and macrophage activation with tocilizumab

Transfus Med. 2022 Oct;32(5):437-440. doi: 10.1111/tme.12793. Epub 2021 May 27.

Authors

Frederick Chen^{1

2}, Catherine Booth^{1

3}, Filipa Barroso¹, Sarah Bennett¹, Banu Kaya^{1

2}, Nay Win⁴, Paul Telfer^{1

2}

Affiliations

¹ Department of Clinical Haematology, Royal London Hospital, Barts Health NHS Trust, London, UK.
² Queen Mary University London, London, UK.
³ NHS Blood and Transplant, London, UK.
⁴ NHS Blood and Transplant, Tooting Centre, London, UK.

PMID: 34046955
DOI: 10.1111/tme.12793

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Hemolysis
Humans
Macrophage Activation*
Transfusion Reaction*

Substances

Antibodies, Monoclonal, Humanized
tocilizumab